CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Select Drug-Drug Interactions With Direct Oral Anticoagulants Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial Variation in Revascularization Practice and Outcomes in Asymptomatic Stable Ischemic Heart Disease Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus Mode of Death in Heart Failure With Preserved Ejection Fraction Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert Panel

Original Research30 Jul 2018 [Epub ahead]

JOURNAL:Circulation. Article Link

The Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator

A Khera , MJ Budoff , CJ O’Donnell et al. Keywords: coronary artery calcium; risk prediction

ABSTRACT


BACKGROUND - Coronary artery calcium (CAC) is a powerful novel risk indicator for atherosclerotic cardiovascular disease (ASCVD). Currently, there is no available ASCVD risk prediction tool that integrates traditional risk factors and CAC.


METHODS - To develop a CAC ASCVD risk tool for younger individuals in the general population, subjects aged 40-65 without prior CVD from three population-based cohorts were included. Cox proportional hazards models were developed incorporating age, sex, systolic blood pressure, total and HDL cholesterol, smoking, diabetes, hypertension treatment, family history of MI, high-sensitivity CRP (hs-CRP), and CAC scores (Astro-CHARM model) as dependent variables and ASCVD (non-fatal/fatal MI or stroke) as the outcome. Model performance was assessed internally, and validated externally in a fourth cohort.

RESULTS - The derivation study comprised 7382 individuals with mean age 51 years, 45% female, and 55% non-white. The median CAC was 0 (25-75th [0,9]) and 304 ASCVD events occurred in median 10.9 years of follow-up. The c-statistic was 0.784 for the risk factor model, and 0.817 for Astro-CHARM (p<0.0001). Compared with the risk factor model, the Astro-CHARM model resulted in integrated discrimination improvement (IDI=0.0252) as well as net reclassification improvement (NRI=0.121, p<0.0001). The Astro-CHARM model demonstrated good discrimination (c=0.78) and calibration (Nam-D’Agostino χ2:13.2, p=0.16) in the validation cohort (n=2057; 55 events). A mobile application and web-based tool were developed to facilitate clinical application of this tool ( www.AstroCHARM.org).

CONCLUSIONS - The Astro-CHARM tool is the first integrated ASCVD risk calculator to incorporate risk factors, including hs-CRP and family history, and CAC data. It improves risk prediction compared with traditional risk factor equations and could be useful in risk-based decision making for CV disease prevention in the middle-aged general population.